Details of the Drug

General Information of Drug (ID: DMLGEQ7)

Drug Name
TAK-861
Indication
Disease Entry ICD 11 Status REF
Narcolepsy type 1 7A20.0 Phase 2 [1]
Narcolepsy type 2 7A20.1 Phase 2 [2]
Drug Type
Small molecule
Cross-matching ID
PubChem CID
154617563
TTD ID
DZ35AP
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Orexin receptor type 2 (HCRTR2) TT9N02I OX2R_HUMAN Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05687903) A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05687916) A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2). U.S.National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight